Evidence map›Paper›PMID 36555588›Full record

ReviewInternational journal of molecular sciences2022

Alarmins as a Possible Target of Future Therapies for Atrial Fibrillation.

Egidio Imbalzano, Giuseppe Murdaca, Luana Orlando, Marianna Gigliotti-De Fazio, Dario Terranova, Alessandro Tonacci, Sebastiano Gangemi

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Egidio ImbalzanoDepartment of Clinical and Experimental Medicine, University of Messina, n. Viale Benedetto XV, n. 6, 98125 Messina, Italy.ORCID 0000-0003-2656-5467
Giuseppe MurdacaDepartment of Internal Medicine, Ospedale Policlinico San Martino, University of Genova, 16132 Genova, Italy.ORCID 0000-0002-6403-6905
Luana OrlandoDepartment of Clinical and Experimental Medicine, University of Messina, n. Viale Benedetto XV, n. 6, 98125 Messina, Italy.
Marianna Gigliotti-De FazioDepartment of Clinical and Experimental Medicine, University of Messina, n. Viale Benedetto XV, n. 6, 98125 Messina, Italy.
Dario TerranovaDepartment of Clinical and Experimental Medicine, University of Messina, n. Viale Benedetto XV, n. 6, 98125 Messina, Italy.
Alessandro TonacciClinical Physiology Institute, National Research Council of Italy (IFC-CNR), 56124 Pisa, Italy.ORCID 0000-0001-8335-5541
Sebastiano GangemiDepartment of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy.
University of Messina · ITIstituto di Fisiologia Clinica · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To date, worldwide, atrial fibrillation is the most common cardiovascular disease in adults, with a prevalence of 2% to 4%. The trigger of the pathophysiological mechanism of arrhythmia includes several factors that sustain and exacerbate the disease. Ectopic electrical conductivity, associated with the resulting atrial mechanical dysfunction, atrial remodeling, and fibrosis, promotes hypo-contractility and blood stasis, involving micro endothelial damage. This causes a significant local inflammatory reaction that feeds and sustains the arrhythmia. In our literature review, we evaluate the role of HMGB1 proteins, heat shock proteins, and S100 in the pathophysiology of atrial fibrillation, offering suggestions for possible new therapeutic strategies. We selected scientific publications on the specific topics "alarmins" and "atrial fibrillation" from PubMed. The nonsystematic review confirms the pivotal role of molecules such as S100 proteins, high-mobility group box-1, and heat shock proteins in the molecular pattern of atrial fibrillation. These results could be considered for new therapeutic opportunities, including inhibition of oxidative stress, evaluation of new anticoagulant drugs with novel therapeutic targets, molecular and genetic studies, and consideration of these alarmins as predictive or prognostic biomarkers of disease onset and severity.

Indexed as

Atrial FibrillationAlarminsHeart AtriaHeat-Shock ProteinsHumansInflammationAlarminsHeat-Shock Proteinsalarminsatrial fibrillationheat shock proteinsHMGB1S100 protein

Identifiers

PMID36555588
PMCPMC9780784
OpenAlexW4311510934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.